Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
dc.contributor.author | Seeff, Leonard B. | en_US |
dc.contributor.author | Curto, Teresa M. | en_US |
dc.contributor.author | Szabo, Gyongyi | en_US |
dc.contributor.author | Everson, Gregory T. | en_US |
dc.contributor.author | Bonkovsky, Herbert L. | en_US |
dc.contributor.author | Dienstag, Jules L. | en_US |
dc.contributor.author | Shiffman, Mitchell L. | en_US |
dc.contributor.author | Lindsay, Karen L. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Di Bisceglie, Adrian M. | en_US |
dc.contributor.author | Lee, William M. | en_US |
dc.contributor.author | Ghany, Marc G. | en_US |
dc.date.accessioned | 2008-03-06T19:09:53Z | |
dc.date.available | 2009-02-03T16:28:50Z | en_US |
dc.date.issued | 2008-02 | en_US |
dc.identifier.citation | Seeff, Leonard B.; Curto, Teresa M.; Szabo, Gyongyi; Everson, Gregory T.; Bonkovsky, Herbert L.; Dienstag, Jules L.; Shiffman, Mitchell L.; Lindsay, Karen L.; Lok, Anna S. F.; Di Bisceglie, Adrian M.; Lee, William M.; Ghany, Marc G. (2008). "Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial Potential conflict of interest: Financial relationships of the authors with Hoffmann-La Roche Inc., are as follows: G. Szabo receives research support; G.T. Everson is a consultant, on the speaker's bureau, and receives research support; M.L. Shiffman is a consultant, on the speaker's bureau, and receives research support; K.L. Lindsay is a consultant and receives research support; A.S.F. Lok is a consultant and receives research support; A.M. Di Bisceglie is a consultant, on the speaker's bureau, and receives research support; and W.M. Lee receives research support. Authors with no financial relationships with Hoffmann-La Roche Inc. to disclose are: L.B. Seeff, T.M. Curto, H.L. Bonkovsky, J.L. Dienstag, and M.G. Ghany. Dr. Lee is a consultant for Lilly AstraZeneca. Dr. Lok is a consultant for and received grants from Schering-Plough. Dr. Lindsay is a consultant for and received grants from Valeant Pharmaceuticals. She received grants from Vertex Pharmaceuticals, Human Genome Sciences. She is also a consultant for Zymogenetics, Kendle International, and King Pharmaceuticals, Inc. Dr. Shiffman received grants from Schering-Plough and Vertex. He advises and received grants from Valeant, Wyeth, and Novartis. Dr. Dienstag advises GlaxoSmithKline, Bristol-Myers Squibb, Idenix Pharmaceuticals, Achillion Pharmaceuticals, Metabasis Therapeutics, SciClone, Nucleonics, and Valeant. She is a consultant for Oxxon Therapeutics, ComninatoRx, and Pharmasset. She also advises and received grants from Vertex. This is publication number 27 from the HALT-C Trial Group. ." Hepatology 47(2): 605-612. <http://hdl.handle.net/2027.42/58026> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58026 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18157835&dopt=citation | en_US |
dc.description.abstract | Herbal products, used for centuries in Far Eastern countries, are gaining popularity in western countries. Surveys indicate that persons with chronic hepatitis C (CHC) often use herbals, especially silymarin (milk thistle extract), hoping to improve the modest response to antiviral therapy and reduce side effects. The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial, involving persons with advanced CHC, nonresponders to prior antiviral therapy but still willing to participate in long-term pegylated interferon treatment, offered the opportunity to examine the use and potential effects of silymarin. Among 1145 study participants, 56% had never taken herbals, 21% admitted past use, and 23% were using them at enrollment. Silymarin constituted 72% of 60 herbals used at enrollment. Among all participants, 67% had never used silymarin, 16% used it in the past, and 17% used it at baseline. Silymarin use varied widely among the 10 participating study centers; men were more frequent users than women, as were non-Hispanic whites than African Americans and Hispanics. Silymarin use correlated strongly with higher education. No beneficial effect of silymarin was found on serum alanine aminotransferase or hepatitis C virus (HCV) RNA levels. Univariate analysis showed significantly fewer liver-related symptoms and better quality-of-life parameters in users than nonusers, but after reanalysis adjusted for covariates of age, race, education, alcohol consumption, exercise, body mass index, and smoking, only fatigue, nausea, liver pain, anorexia, muscle and joint pain, and general health remained significantly better in silymarin users. In conclusion, silymarin users had similar alanine aminotransferase and HCV levels to those of nonusers but fewer symptoms and somewhat better quality-of-life indices. Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C. (H EPATOLOGY 2008.) | en_US |
dc.format.extent | 246766 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD ; fax:301-480-7926 ; NIDDK, NIH, 31A Center Drive, Room 9A27, Bethesda, MD 20892 | en_US |
dc.contributor.affiliationother | New England Research Institutes, Watertown, MA | en_US |
dc.contributor.affiliationother | Hepatology and Liver Center, Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA | en_US |
dc.contributor.affiliationother | Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO | en_US |
dc.contributor.affiliationother | Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT | en_US |
dc.contributor.affiliationother | Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, MA | en_US |
dc.contributor.affiliationother | Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA | en_US |
dc.contributor.affiliationother | Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO | en_US |
dc.contributor.affiliationother | Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.identifier.pmid | 18157835 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58026/1/22044_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.22044 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.